The COVID-19 pandemic highlighted the successful development and utilisation of mRNA vaccines. This has encouraged biopharmaceutical companies to explore and utilise these technologies for other diseases. There are a significant number of new therapeutic programmes that are based on mRNA and lipids, which is encouraging CDMOs to invest in new expertise to deliver end-to-end solutions.
CDMOs have been building new capacity, while simultaneously building out capabilities, to better prepare for the new wave of technologies. Many CDMOs have invested in new processes and resources to safeguard product integrity, minimise waste, enable safe and efficacious supply to patients without delay.
“In the area of mRNA technology, we have seen CDMOs do almost exclusive internal builds, while others are making strategic acquisitions to develop their mRNA capabilities. Many CDMOs, like the Center for Breakthrough Medicines, are expanding to include this dedicated and segregated capacity. It is extraordinarily complex and a different process from other processes CDMOs are currently running, so you must make sure to segregate these operations as much as possible from your existing manufacturing,” said Joerg Ahlgrimm, President and CEO, Center for Breakthrough Medicines, US.
With mRNA-based drugs witnessing a surge in popularity in such a short time frame, companies supporting their development and manufacturing had to adapt quickly as mRNA- based vaccines required cold chain capabilities and more robust aseptic fillfinish technologies.
Weathering the storm
Even though COVID-19 fuelled the growth for the CDMO market, it also brought its fair share of challenges.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
"We are dedicated to helping people of all ages see brilliantly"
The global leader in eye care for over 75 years, Alcon Inc. strives to help eye care professionals strengthen their practices and serve patients better, improving visual health worldwide. Through its innovative eye care portfolios, Alcon has established operations in 56 countries and serves patients in 140 countries. Jason Hoffe, Vice President, APAC Vision Care, Alcon, responsible for driving the vision care business in the region shares opportunities exist for the company and new developments in eye healthcare that are cause for optimism for patients in the region.
Singapore Turns Tech Beacon with Revolutionary Pharma Manufacturing & Digital Transformation
In the current pharmaceutical manufacturing environment, linking information technology (IT) with operational technology (OT) systems is increasingly vital. This integration enables a seamless exchange of information between these two historically separate domains - one focused on data management and the other on overseeing physical operations. This enables various aspects of the manufacturing process to gain insights from one another to boost efficiency and refine strategic decision-making. Digital transformation is essential for directing companies through the complexities of implementation and ensuring a seamless shift to a data-driven, digitally optimized manufacturing landscape.
Building the Future of Medicine
PRODUCT OF THE YEAR 2024 - Needle Free Injection System technology by IntegriMedical
Emerging Leader in Cell & Gene Therapy
STARTUP OF THE YEAR 2024 - ImmunoACT
Improving Access for Respiratory Healthcare
STARTUP OF THE YEAR 2024 - Aevice Health
Making an Impact with a 'CliKX'
Dr Lynne Lim, Co-Founder & Chief Executive Officer, NousQ
Eyeing 20-20 Vision of Excellence
Dr Jogin Desai, Co-Founder & Chief Executive Officer, Eyestem Research
Refining the Use of Radiation
Dr Christian Behrenbruch, Managing Director and Group Chief Executive Officer (CEO), Telix Pharmaceuticals
Honouring Innovators in Asia's Thriving Life Sciences Sector
Asia has, indeed, become the new hub for growth and innovation, with no signs of losing steam. To recognise the Asian companies and individuals for their commendable performance and achievements during 2023 and 2024, BioSpectrum Asia Excellence Awards 2024 ceremony was held at Hotel Fort Canning in Singapore on December 6, 2024.
How To Control Indian Diabetes Growth
World Diabetes Day, observed on November 14, reminds us of the growing impact of diabetes on global health and the urgent need for collective action to prevent, diagnose, and manage this chronic condition. In 2024, the theme 'Breaking Barriers, Bridging Gaps' underscores the critical importance of accessible, high-quality diabetes care, especially for underrepresented communities. The Government of India has taken many measures intending to reduce the prevalence of diabetes and alleviate its long-term complications, contributing to a healthier future for all citizens.
